Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.00 (0.00%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £91.78m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

Suspension - Faron Pharmaceuticals Oy

30 Mar 2026 07:30

RNS Number : 5226Y
AIM
30 March 2026
 

NOTICE

 

30/03/2026 7:30am

 

TEMPORARY SUSPENSION OF TRADING ON AIM

 

FARON PHARMACEUTICALS OY

 

At the request of the Company, trading on AIM for the under-mentioned securities was temporarily suspended from 30/03/2026 7:30am, pending an announcement.

 

SUBSCRIPTION RIGHTS, NIL PAID (DI)

(BS84X55) (FI4000602313)

If you have any queries relating to the above, please contact the Company's nominated adviser on +44 (0) 207 213 0880.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
EXCJRMRTMTJTBIF
Date   Source Headline
6th Feb 20237:00 amRNSNotice of 2022 Full-Year Results and Annual Report
1st Feb 20233:45 pmRNSHolding(s) in Company
27th Jan 20235:45 pmRNSHolding(s) in Company
27th Jan 20237:00 amRNSResults of Placing
26th Jan 20234:30 pmRNSProposed Issue and Placing
16th Jan 202311:00 amRNSPrice Monitoring Extension
16th Jan 20239:05 amRNSSecond Price Monitoring Extn
16th Jan 20239:00 amRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSTitle: BEXMAB study update
23rd Dec 20227:00 amRNSFaron’s Financial Calendar for 2023
5th Dec 20227:00 amRNSBEXMAB Study Update
1st Dec 20227:00 amRNSFaron Appoints Maija Hollmén PhD as CSO
18th Nov 20224:30 pmRNSAmendment Terms and Conditions with IPF Partners
2nd Nov 20227:00 amRNSFaron Announces Poster Presentation at SITC
31st Oct 20227:00 amRNSBEXMAB Study Update
19th Oct 20229:20 amRNSHolding(s) in Company
18th Oct 202212:30 pmRNSHolding(s) in Company
18th Oct 20227:00 amRNSFaron Announces Melanoma Cohort Data from MATINS
14th Oct 20227:00 amRNSResults of Placing
13th Oct 20225:31 pmRNSProposed Issue and Placing of Shares
22nd Sep 20227:00 amRNSGrant of Options
20th Sep 20227:00 amRNSTop-Line Data on Bexmarilimab Dose Variation
14th Sep 20227:00 amRNSFaron to Host Bexmarilimab Update Webcast
13th Sep 20227:00 amRNSTraumakine Data Presented at MHSR Symposium
7th Sep 20221:00 pmRNSFaron to Present at Upcoming Conferences
25th Aug 20227:00 amRNSFaron Reports 2022 Half-Year Financial Results
8th Aug 20227:00 amRNSNotice of Half-Year Financial Results
7th Jul 20229:45 amRNSResults of EGM
30th Jun 20225:00 pmRNSHolding(s) in Company
28th Jun 20221:47 pmRNSRegistration of New Shares
28th Jun 20227:00 amRNSAnnouncement of Placing
16th Jun 202212:00 pmRNSFaron notice of EGM
15th Jun 20227:00 amRNSFaron Announces Top-Line 12-Month Survival Results
8th Jun 20227:00 amRNSFirst Patient Dosed in Ph I/II BEXMAB Combo Study
1st Jun 20227:00 amRNSExercise of options
30th May 20227:00 amRNSPresentation of Biomarker Analysis at ASCO
16th May 20227:00 amRNSFDA and FIMEA approve BEXMAB study to begin
12th May 20223:50 pmRNSEx Vivo Data Presented at EHA2022 Congress
9th May 20227:00 amRNSMol Cancer Ther Publishes Bexmarilimab Research
4th May 202211:15 amRNSGrant of options
22nd Apr 20221:01 pmRNSBoard Changes
22nd Apr 20221:00 pmRNSResults of AGM
21st Apr 20224:30 pmRNSFaron Presents Melanoma Data at EADO
8th Apr 20223:45 pmRNSManagers’ Transactions
5th Apr 20227:00 amRNSFaron Closes HIBISCUS Trial
25th Mar 20229:00 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20227:15 amRNSFaron´s Annual Report 2021 Published
25th Mar 20227:00 amRNSFinancial Statement January 1 to December 31 2021
14th Mar 20227:00 amRNSFaron Publishes Research From INTEREST Trial
9th Mar 20227:00 amRNSPresentation of Biomarker Data at AACR 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.